Abstract: The invention concerns sulphonamides of general formula ##STR1## and their pharmaceutically acceptable acid addition salts. In formula (I), R represents hydrogen or lower alkyl, R.sup.1 and R.sup.2 which may be the same or different each represents hydrogen, lower alkyl, lower alkoxy or halogen, R.sup.3 and R.sup.4 which may be the same or different each represents lower alkyl, halo(lower)alkyl or aryl, A represents a lower alkylene group having 1 to 3 carbon atoms in the chain between the two N atoms and X represents O, S or NR.sup.5 (where R.sup.5 is hydrogen or lower alkyl). The compounds possess .alpha..sub.2 -adrenoceptor antagonistic activity in warm blooded animals.

Abstract: The invention relates to compounds of formula ##STR1## or a salt thereof, wherein .dbd.X-- is .dbd.CH-- or .dbd.N--, R and R.sup.1 independently represent hydrogen, halogen or lower alkoxy and R.sup.2 is hydrogen or a substituent selected from halogen, lower alkyl, lower alkoxy or halolower alkyl which compounds exhibit psychotropic activity and are useful as antidepressants.

Abstract: The invention concerns indole derivatives of formula I ##STR1## in which R.sub.1 is hydrogen, lower alkyl, halogen, lower alkoxy or hydroxy,R.sub.2, R.sub.3 and R.sub.4 independently represent hydrogen or lower alkyl,A represents an alkylene, oxoalkylene or hydroxyalkylene chain each having 2 to 6 carbon atoms or a pharmaceutically acceptable salt thereof, which compounds possess antihypertensive activity while exhibiting reduced CNS depressant properties.Also disclosed are methods for preparing the compounds of formula I and pharmaceutical compositions containing them.

Abstract: The invention concerns the preparation of compounds of formula ##STR1## and acid addition and quaternary ammonium salts thereof, wherein the dotted line represents an optional bond, Ar represents a ring system of formula ##STR2## in which Q is O, S, --CR.sup.7 .dbd.CR.sup.8 --, --N.dbd.CR.sup.8 -- and --N.dbd.N--; R.sup.4, R.sup.5 and R.sup.6, and R.sup.7 and R.sup.8 when present, each represent hydrogen or a substituent selected from lower alkyl, lower alkenyl, lower alkoxy, NO.sub.2, NH.sub.2, haloloweralkyl, hydroxyloweralkyl, aminoloweralkyl, substituted amino, halogen, loweralkoxycarbonyl, cyano, CONH.sub.2 and hydroxy; and additionally either R.sup.4 and R.sup.5 when adjacent or R.sup.6 and R.sup.

Abstract: This invention concerns a method of treatment using 1,4-dihydropyridine derivatives having the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein R is aryl or heteroaryl;R.sup.1 and R.sup.2 are each independently C.sub.1 -C.sub.4 alkyl or 2-methoxyethyl;Y is --(CH.sub.2).sub.n --, --CH.sub.2 CH(CH.sub.3)-- or --CH.sub.2 C(CH.sub.3).sub.2 --;X is a 5 or 6 membered nitrogen containing aromatic heterocyclic ring which may optionally be substituted by one or more C.sub.1 -C.sub.4 alkyl, phenyl, benzyl, CN, --N(R.sup.3).sub.2, (CH.sub.2).sub.m CO.sub.2 H, (CH.sub.2).sub.m CO.sub.2 (C.sub.1 -C.sub.4 alkyl) or (CH.sub.2).sub.m CON(R.sup.3).sub.2 groups wherein each R.sup.3 is independently H or C.sub.1 -C.sub.4 alkyl and m is 0 or 1;and n is 1 to 3 when X is linked by a ring carbon atom or 2 or 3 when X is linked by a ring nitrogen atom.

Abstract: The invention concerns benzoquinolizines of general formula ##STR1## or their pharmaceutically acceptable acid addition salts. In the formula R.sup.1 and R.sup.2 which may be the same or different each represent hydrogen, lower alkyl, lower alkoxy or halogen, R.sup.3 represents lower alkyl and R.sup.4 is lower alkoxy or lower alkoxy carbonyl. The compounds possess .alpha..sub.2 -adrenoceptor antagonistic activity in warm blooded animals.

Abstract: The invention concerns the preparation of compounds of formula ##STR1## and acid addition and quaternary ammoniun salts thereof, wherein the dotted line represents an optional bond, Ar represents a ring system of formula ##STR2## in which Q is O, S, --CR.sup.7 .dbd.CR.sup.8 --, --N.dbd.CR.sup.8 -- and --N.dbd.N--; R.sup.4, R.sup.5 and R.sup.6, and R.sup.7 and R.sup.8 when present, each represent hydrogen or a substituent selected from lower alkyl, lower alkenyl, lower alkoxy, NO.sub.2, NH.sub.2, haloloweralkyl, hydroxyloweralkyl, aminoloweralkyl, substituted amino, halogen, loweralkoxycarbonyl, cyano, CONH.sub.2 and hydroxy; and additionally either R.sup.4 and R.sup.5 when adjacent or R.sup.6 and R.sup.

Abstract: The invention concerns benzoquinolizines of general formula ##STR1## and their pharmaceutically acceptable acid addition salts. In formula (I), R represents hydrogen or lower alkyl, R.sup.1 and R.sup.2 which may be the same or different each represent hydrogen, lower alkyl, lower alkoxy or halogen, R.sup.3 and R.sup.4 which may be the same or different each represents lower alkyl, halo(lower)alkyl or aryl and A represents a lower alkylene group having 1 to 3 carbon atoms in the chain between the two N atoms. The compounds possess .alpha..sub.2 -adrenoceptor antagonistic activity in warm blooded animals.

Abstract: The invention concerns benzoquinolizines of formula ##STR1## and their pharmaceutically acceptable acid addition salts. In the formula R.sup.1 and R.sup.2 which may be the same or different each represent hydrogen, lower alkyl, lower alkoxy or halogen, R.sup.3 represents methyl or ethyl, A represents a direct bond between the S and N atoms or a lower alkylene group having 1 to 3 carbon atoms in the chain between the S and N atoms, R.sup.4 and R.sup.5 each independently represent hydrogen, lower alkyl, aryl or aryl(lower)alkyl or together with the nitrogen atom to which they are attached represent a five or six membered heterocyclic ring. The compounds possess .alpha..sub.2 -adrenoceptor antagonistic activity and can be incorporated into pharmaceutical compositions.

Abstract: The invention concerns benzoquinolizines of formula ##STR1## and their pharmaceutically acceptable acid addition salts. In the formula, R.sup.1 and R.sup.2 which may be the same or different, each represent hydrogen, lower alkyl, lower alkoxy or halogen, R.sup.3 represents methyl or ethyl and R.sup.4 represents halo(lower)alkyl. The compounds possess .alpha..sub.2 -adrenoceptor antagonistic activity and can be incorporated into pharmaceutical compositions.

Abstract: The invention concerns benzoquinolizines of formula ##STR1## and their acid addition salts. In the formula R.sup.7 is lower alkyl or a phenyl or naphthyl radical optionally substituted with specified substituents and R.sup.8 is methyl or ethyl. The compounds possess high .alpha..sub.2 (presynaptic) adrenoceptor antagonistic activity and a good .alpha..sub.2 /.alpha..sub.1 antagonistic selectivity.

Abstract: Guanidines of formula ##STR1## and their pharmaceutically acceptable acid addition salts, (wherein R.sup.1 and R.sup.2 each represents lower alkyl or trifluoromethyl and R.sup.3 and R.sup.4 each represents hydrogen or lower alkyl or R.sup.3 and R.sup.4 together represent dimethylene or trimethylene) are useful in treating or preventing diarrhoea in mammals or poultry. The compound, if desired, may be administered with one or more antimicrobial, adsorbent, anti-emetic, parasympatholytic or antihistaminic agents.

Abstract: The invention concerns compounds of formula ##STR1## or pharmaceutically acceptable salts thereof, wherein Ar represents an optionally substituted indolyl group; A represents a straight or branched chain alkylene or oxoalkylene group, each having 2-4 carbon atoms and R represents an optionally substituted aryl (including heteroaryl) group, which possess anti-hypertensive and psychotropic activity, and are useful in the treatment of high blood pressure or as anti-depressants.

Abstract: Xanthine derivatives are provided which exhibit psychotropic activity in that they inhibit 5-hydroxytryptamine reuptake in vitro and are indicated for antidepressive use.

Abstract: The invention relates to compounds of formula II ##STR1## and their pharmaceutically acceptable salts wherein R.sup.5 represents hydrogen, acyl, lower alkyl or cycloalkyl; R.sup.6 represents hydrogen, halogen, trifluormethyl, or lower alkyl; R.sup.7 represents hydrogen, lower alkyl, hydroxy, lower alkoxy, arylloweralkoxy; R.sup.8 represents hydrogen or lower alkyl; and R.sup.9 represents hydrogen or lower alkyl.The compounds have dopamine blockade activity and may be used in the treatment of psychoses including schizophrenia.

Abstract: Compounds having the formula ##STR1## wherein Y represents --CHOH-- or ##STR2## Z and Z.sup.1 independently represent ##STR3## --SO.sub.2 --, --COCH.sub.2 --, or --CO(CH.sub.2).sub.2 --; Z may also represent --CH.sub.2 --, --(CH.sub.2).sub.2, --CHMe--, or --CMe.sub.2 --; R.sup.1 and R.sup.2 independently represent hydrogen or substituents selected from halogen, lower-alkoxy, nitro, amino, lower alkylamino, trifluoromethyl, hydroxy, aryl lower alkoxy and lower alkyl; or R.sup.1 and R.sup.2 when adjacent together with the carbon atoms to which they are attached form a six membered carbocyclic ring; R.sup.3 represents hydrogen, halogen, lower alkyl or lower alkoxy, R.sup.4 represents lower alkyl or hydrogen; .alpha. and .beta. each represent hydrogen or a direct bond between the carbon atoms to which they are attached, and acid addition quaternary ammonium salts thereof, are disclosed which possess antihypertensive activity.

Abstract: Novel cyanoguanidine derivatives having the formula ##STR1## wherein Ar is a phenyl or pyrrol-1-yl group substituted by one or more substituents selected from halogen, trifluoromethyl, lower alkyl, lower alkoxy and nitro and R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are each independently hydrogen or lower alkyl or R.sub.1 and R.sub.2 taken together form dimethylene or trimethylene, lower blood pressure and, in some cases are also anti-ulcer agents.

Abstract: The invention concerns benzoquinolizines of the general formula (I) ##STR1## and the pharmaceutically acceptable acid addition salts thereof, wherein the ##STR2## linkage represents a single bond linkage of formula ##STR3## or a double bond linkage of formula ##STR4## R.sup.1 and R.sup.2 which may be the same or different each represent hydrogen, lower alkyl, lower alkoxy or halogen, R.sup.3 and R.sup.4 which may be the same or different each represent hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, lower alkylamino, di(lower)alkylamino or trifluoromethyl and X is O, S or NH. The compounds possess anti-secretory activity.

Abstract: Compounds of formula: ##STR1## and pharmaceutically acceptable acid addition or quaternary ammonium salts thereof wherein the piperidine ring is substituted in the 3 or 4 position; X represents .dbd.CH-- or .dbd.N--; Y represents --NR.sup.5 --, --O-- or --S-- wherein R.sup.5 is hydrogen or lower alkyl; A is lower alkylene or hydroxy lower alkylene, Z and Z.sup.1 independently represent ##STR2## Z may also represent --CH.sub.2 --, --(CH.sub.2).sub.2 --, --CHMe-- or --CMe.sub.2 --; R.sup.1, R.sup.2, R.sup.3 independently represent hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, lower alkylamino, trifluoromethyl, lower-alkanoylamino, hydroxy or aryl lower alkoxy; or R.sup.1 and R.sup.2 when adjacent together with the carbons to which they are attached form a six membered carbocyclic ring; and R.sup.4 represents hydrogen or lower alkyl, are disclosed which possess psychotropic activity and are useful as anti-depressants.

Abstract: Compounds of formula ##STR1## in which X represents oxygen or sulphur;Y represents --CHOH-- or ##STR2## Z represent ##STR3## or a direct bond; R represents cycloalkyl group having 5 to 7 carbon atoms or an optionally substituted aryl or heteroaryl radical, or when --Z-- is a direct bond R also represents hydrogen;R.sup.1 represents hydrogen or lower alkyl;R.sup.2 represents hydrogen, halogen, lower alkyl or lower alkoxy; andR.sup.3 represents hydrogen or lower alkyl, and a pharmaceutically acceptable acid addition or quarternary ammonium salts thereof, are disclosed which possess hypotensive activity.